Ventolin 100 microgramos/inhalación suspensión para inhalación en envase a presión* (*) sin CFC
Sponsors
Areteia Therapeutics Inc., Glaxosmithkline Research & Development Limited, Hospital General Universitario Gregorio Maranon
Conditions
AsthmaChronic obstructive pulmonary diseases with Heart Failure with eyection ventricular ejection fraction between 35-50%Severe eosinophilic asthma
Phase 3
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)
WithdrawnCTIS2023-503693-20-00
Target: 20Updated: 2023-09-12
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)
CompletedCTIS2023-503693-20-01
Start: 2024-04-10End: 2025-11-05Target: 490Updated: 2025-12-16
A randomized, double-blind, parallel group, multi-center study to evaluate the long-term safety of salbutamol rescue medication when administered via metered dose inhalers containing the propellant HFA-152a or reference HFA-134a.
CompletedCTIS2023-509001-76-00
Start: 2024-07-01End: 2025-08-26Target: 227Updated: 2025-09-01